Switching from Vraylar (Cariprazine) to Rexulti (Brexpiprazole)
Yes, switching from cariprazine to brexpiprazole is feasible and may be safer than switching to aripiprazole, particularly in patients with dopamine supersensitivity, though the switch requires careful monitoring in the first 2 weeks due to potential drug interactions with this patient's cardiac medications.
Key Considerations for This Specific Patient
Critical Drug Interaction Warning
The combination of atorvastatin with sacubitril-valsartan carries significant risk for rhabdomyolysis 1. Sacubitril inhibits statin excretion, elevating serum concentrations and increasing muscle toxicity risk. When adding brexpiprazole to this regimen:
- Monitor creatine kinase (CK), liver function, and renal function closely during the switch
- Watch for myalgia, oliguria, or muscle weakness
- Consider reducing atorvastatin to 20 mg daily if not already at this dose
- Rosuvastatin may be a safer alternative to atorvastatin in this combination 1
Switching Strategy
Use a gradual cross-taper approach rather than abrupt switching 2. The evidence shows brexpiprazole can be switched more safely than aripiprazole, with no significant difference in switching failure rates between patients with and without dopamine supersensitivity 3.
Specific dosing protocol 4:
- Week 1: Start brexpiprazole 0.5 mg daily while maintaining current cariprazine dose
- Week 2: Increase brexpiprazole to 1 mg daily, begin tapering cariprazine by 50%
- Week 3: Increase brexpiprazole to 2 mg daily (target dose for schizophrenia), discontinue cariprazine
- Weeks 4-5: Maintain brexpiprazole 2 mg; may increase to 4 mg if needed based on response
Important Pharmacokinetic Consideration
Cariprazine has an extremely long half-life (1-3 weeks for active metabolites), meaning it will continue exerting effects for weeks after discontinuation 5. This actually facilitates a smoother transition and reduces withdrawal-related psychotic exacerbation.
Monitoring Requirements
Baseline (Before Switch)
- BMI, waist circumference, blood pressure
- Fasting glucose or HbA1c
- Lipid panel
- Prolactin level
- Liver function tests
- Creatine kinase (critical given atorvastatin-sacubitril/valsartan interaction)
- Renal function (urea, electrolytes)
- ECG 6
During Switch (Weeks 1-6)
- Weekly: BMI, waist circumference, blood pressure 6
- Week 4: Fasting glucose 6
- Weeks 2,4,6: CK levels (given drug interaction risk) 1
- Daily assessment: Signs of delirium if clozapine is part of the regimen 7
Long-term (After 3 months, then annually)
- Repeat all baseline measures 6
Clozapine Consideration
If clozapine is part of this patient's regimen, exercise extreme caution:
- The combination of clozapine with benzodiazepines (if used) increases risk of cardiorespiratory collapse, aspiration pneumonia, and delirium 7
- Cariprazine has been used successfully as adjunctive therapy to clozapine for negative symptoms and metabolic side effects 8
- Brexpiprazole has not been as extensively studied in combination with clozapine
Advantages of Brexpiprazole Over Cariprazine
- Lower metabolic burden: Brexpiprazole may have a more favorable metabolic profile 8
- Safer switching profile: Patients who failed aripiprazole switches often succeed with brexpiprazole 3
- Established efficacy: FDA-approved for schizophrenia with demonstrated maintenance of effect 4
Red Flags Requiring Immediate Intervention
- Muscle pain, weakness, or dark urine: Stop atorvastatin immediately, check CK urgently
- Worsening psychosis during switch: May indicate treatment-resistant schizophrenia; these patients have higher switching failure rates 3
- Sedation, respiratory depression: Particularly if on clozapine and benzodiazepines 7
Treatment-Resistant Schizophrenia Caveat
If this patient has treatment-resistant schizophrenia, switching failure rates are significantly higher 3. In such cases, clozapine remains the gold standard 9, and switching away from an effective regimen should be reconsidered unless there are compelling reasons (intolerable side effects, metabolic complications).
The metoprolol and sertraline in this regimen pose minimal interaction concerns with brexpiprazole and do not require dose adjustments.